Page last updated: 2024-12-05

2-ethylhexyl salicylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Ethylhexyl salicylate (also known as octyl salicylate) is a chemical compound used as a sunscreen agent and fragrance ingredient. It is synthesized by the esterification of salicylic acid with 2-ethylhexanol. 2-Ethylhexyl salicylate absorbs ultraviolet (UV) radiation, particularly in the UVB range, and helps to protect the skin from sun damage. It is a common ingredient in sunscreen products and is often used in combination with other UV filters. 2-Ethylhexyl salicylate has also been studied for its potential therapeutic effects, including its ability to reduce inflammation and promote wound healing. Its importance lies in its ability to protect against harmful UV radiation, which can contribute to skin cancer and premature aging. Research focuses on its efficacy as a sunscreen agent, its potential toxicity and environmental impact, and its interactions with other ingredients in cosmetic formulations.'

2-ethylhexyl salicylate: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8364
CHEMBL ID1329203
CHEBI ID88639
SCHEMBL ID39594
MeSH IDM0270415

Synonyms (86)

Synonym
AC-12458
ethylhexyl salicylate
ethyl hexyl salicylate
einecs 204-263-4
octisalate [usan]
2-ethylhexyl 2-hydroxybenzoate
brn 2730664
nsc 46151
LS-14437
sunarome o
wln: qr bvo1y4 & 2
nsc46151
sunarome wmo
usaf do-11
118-60-5
2-ethylhexyl salicylate
salicylic acid, 2-ethylhexyl ester
WMO ,
nsc-46151
uvinul
benzoic acid, 2-hydroxy-, 2-ethylhexyl ester
uvinul (tn)
octisalate (usp/inn)
D05226
neo heliopan
escalol
2-ethylhexyl salicylate, 99%
2-ethylhexyl salicylate, >=99%
NCGC00159324-02
NCGC00159324-03
salicylic acid octyl ester
S0387
salicylic acid 2-ethylhexyl ester
A804061
4x49y0596w ,
octisalate
octisalate [usan:usp:inn]
ec 204-263-4
unii-4x49y0596w
cas-118-60-5
dtxsid7040734 ,
tox21_111573
dtxcid5020734
FT-0631674
AKOS015890505
chebi:88639 ,
CHEMBL1329203
S6405
2-hydroxybenzoic acid 2-ethylhexyl ester
2-hydroxy benzoic acid 2-ethylhexyl ester
ethylhexyl salicylate [inci]
octisalate [vandf]
octisalate [mart.]
octisalate [ii]
octyl salicylate [vandf]
ethylhexyl salicylate [vandf]
octisalate [usp monograph]
octisalate [usp-rs]
octisalate [inn]
octisalate [who-dd]
octyl salicylate [mi]
SCHEMBL39594
NCGC00159324-04
tox21_111573_1
CS-4398
uvinul o-18
dermoblock os
escalol 587
neo heliopan os
HY-B0929
octyl salicylate;2-ethylhexyl salicylate
J-509330
mfcd00053300
2-ethylhexyl salicylate, analytical standard
octisalate, united states pharmacopeia (usp) reference standard
octisalate, pharmaceutical secondary standard; certified reference material
salicylic acid-2-ethyl-1-hexyl ester
ethylhexyl salicylic acid
Q27160526
DB11062
2-ethylhexyl2-hydroxybenzoate
STL570066
ethyl5-(4-bromophenyl)isoxazole-3-carboxylate
F85195
EN300-7381990
SY052290

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"To evaluate the beneficial influence of melatonin in topical sunscreen emulsions combined with three common ultraviolet filters."( In vivo and in vitro evaluation of the use of a newly developed melatonin loaded emulsion combined with UV filters as a protective agent against skin irradiation.
Campmany, AC; Martínez, AR; Naveros, BC; Ramírez, ML; Sierra, AF, 2013
)
0.39
" Melatonin permeation was higher from the emulsion containing melatonin combined with a mixture of three ultraviolet filters (MMIX) formulation."( In vivo and in vitro evaluation of the use of a newly developed melatonin loaded emulsion combined with UV filters as a protective agent against skin irradiation.
Campmany, AC; Martínez, AR; Naveros, BC; Ramírez, ML; Sierra, AF, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
"The aim of the present study was to objectively quantify and predict bioavailability of three sunscreen agents (i."( Measurement, analysis and prediction of topical UV filter bioavailability.
Gabard, B; Gilbert, E; Haftek, M; Maibach, HI; Pirot, F; Roussel, L; Salmon, D; Serre, C, 2015
)
0.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" IBU solutions with and without propylene glycol (PG), polyethylene glycol 200 (PEG 200), and/or octisalate (OS) were dosed onto the forearm of participants."( The effect of formulation excipients on the penetration and lateral diffusion of ibuprofen on and within the stratum corneum following topical application to humans.
Finnin, BC; Gee, CM; Nicolazzo, JA; Watkinson, AC, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (4 Product(s))

Product Categories

Product CategoryProducts
Beauty & Personal Care4

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Andalou Naturals 1000 Roses Daily Shade Facial Lotion SPF 18 -- 2.7 fl ozAndalou NaturalsBeauty & Personal Careoctisalate, orange, allantoin, chamomile, vitamin C, cetyl alcohol, tocopherol, panthenol, ethylhexylglycerin, tocopherol, dimethicone, octocrylene, phenethyl alcohol, stearic acid, stearyl alcohol2024-11-29 10:47:42
The Seaweed Bath Co Active Defense Cream SPF 50 -- 3.4 fl ozThe Seaweed Bath CoBeauty & Personal Careoctisalate, citric acid, benzyl alcohol, cetearyl alcohol, citric acid, vitamin E, decyl glucoside, dehydroacetic acid, vitamin E, glyceryl stearate, glycerin, hydroxyethylcellulose, zinc oxide2024-11-29 10:47:42
The Seaweed Bath Co Clear Guard SPF 40 Sport -- 6 fl ozThe Seaweed Bath CoBeauty & Personal Careoctisalate, vitamin E, vitamin E, methyl abietate, octocrylene2024-11-29 10:47:42
The Seaweed Bath Co Daily Protection Cream SPF 30 -- 3.4 fl ozThe Seaweed Bath CoBeauty & Personal Careoctisalate, citric acid, benzyl alcohol, cetearyl alcohol, citric acid, vitamin E, decyl glucoside, dehydroacetic acid, vitamin E, glyceryl stearate, glycerin, hydroxyethylcellulose, zinc oxide2024-11-29 10:47:42

Drug Classes (2)

ClassDescription
benzoate esterEsters of benzoic acid or substituted benzoic acids.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency23.71010.000221.22318,912.5098AID1259243
estrogen nuclear receptor alphaHomo sapiens (human)Potency16.78550.000229.305416,493.5996AID743079
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency76.95880.000627.21521,122.0200AID651741
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency16.13660.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency10.00000.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1659751Agonist activity at TRPA1 (unknown origin) at 1000 uM relative to AITC2020Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11
Identification of a new class of non-electrophilic TRPA1 agonists by a structure-based virtual screening approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (53)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (11.32)18.2507
2000's10 (18.87)29.6817
2010's25 (47.17)24.3611
2020's12 (22.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.86 (24.57)
Research Supply Index4.08 (2.92)
Research Growth Index5.01 (4.65)
Search Engine Demand Index99.52 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (61.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (3.57%)5.53%
Reviews2 (3.57%)6.00%
Case Studies5 (8.93%)4.05%
Observational0 (0.00%)0.25%
Other47 (83.93%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Assessment of the Human Systemic Absorption of Sunscreen Ingredients [NCT03582215]Phase 172 participants (Actual)Interventional2018-07-18Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT03582215 (7) [back to overview]Avobenzone Maximum Concentration
NCT03582215 (7) [back to overview]Ecamsule Maximum Concentration
NCT03582215 (7) [back to overview]Homosalate Maximum Concentration
NCT03582215 (7) [back to overview]Octinoxate Maximum Concentration
NCT03582215 (7) [back to overview]Octisalate Maximum Concentration
NCT03582215 (7) [back to overview]Octocrylene Maximum Concentration
NCT03582215 (7) [back to overview]Oxybenzone Maximum Concentration

Avobenzone Maximum Concentration

Maximum concentration (observed peak drug concentration) (Cmax) (NCT03582215)
Timeframe: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1; same time points and 216, 312, and 480 h for Part 2

Interventionng/mL (Geometric Mean)
Part 1: Cream1.8
Part 1: Lotion4.3
Part 1: Spray 14.0
Part 1: Spray 23.4
Part 2: Lotion7.1
Part 2: Aerosol Spray3.5
Part 2: Nonaerosol Spray3.5
Part 2: Pump Spray3.3

[back to top]

Ecamsule Maximum Concentration

Maximum concentration (observed peak drug concentration) (Cmax) (NCT03582215)
Timeframe: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1

Interventionng/mL (Geometric Mean)
Part 1: Cream1.5

[back to top]

Homosalate Maximum Concentration

Maximum concentration (observed peak drug concentration) (Cmax) (NCT03582215)
Timeframe: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, 144, 216, 312, and 480 h for Part 2

Interventionng/mL (Geometric Mean)
Part 1: Spray 140.3
Part 2: Aerosol Spray23.1
Part 2: Nonaerosol Spray17.9
Part 2: Pump Spray13.9

[back to top]

Octinoxate Maximum Concentration

Maximum concentration (observed peak drug concentration) (Cmax) (NCT03582215)
Timeframe: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, 144, 216, 312, and 480 h for Part 2

Interventionng/mL (Geometric Mean)
Part 2: Nonaerosol Spray7.9
Part 2: Pump Spray5.2

[back to top]

Octisalate Maximum Concentration

Maximum concentration (observed peak drug concentration) (Cmax) (NCT03582215)
Timeframe: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, 144, 216, 312, and 480 h for Part 2

Interventionng/mL (Geometric Mean)
Part 1: Spray 110.0
Part 2: Aerosol Spray5.1
Part 2: Nonaerosol Spray5.8
Part 2: Pump Spray4.6

[back to top]

Octocrylene Maximum Concentration

Maximum concentration (observed peak drug concentration) (Cmax) (NCT03582215)
Timeframe: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1; same time points and 216, 312, and 480 h for Part 2

Interventionng/mL (Geometric Mean)
Part 1: Cream5.7
Part 1: Lotion5.7
Part 1: Spray 12.9
Part 1: Spray 27.8
Part 2: Lotion7.8
Part 2: Aerosol Spray6.6
Part 2: Nonaerosol Spray6.6

[back to top]

Oxybenzone Maximum Concentration

Maximum concentration (observed peak drug concentration) (Cmax) (NCT03582215)
Timeframe: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1; same time points and 216, 312, and 480 h for Part 2

Interventionng/mL (Geometric Mean)
Part 1: Lotion169.3
Part 1: Spray 1209.6
Part 1: Spray 2194.9
Part 2: Lotion258.1
Part 2: Aerosol Spray180.1

[back to top]